Emerging Pharmaceutical Market in Argentina - Domestic Pharmaceutical Companies Dominate the Market with More Than 55% of the Industry Revenue

Summary

GBI Researchs new report, Emerging Pharmaceutical Market in Argentina - Domestic Pharmaceutical Companies Dominate the Market with More Than 55% of the Industry Revenue provides in-depth analysis of trends, issues and challenges in the pharmaceutical market in Argentina. The report analyzes the overall pharma and clinical trials market in Argentina. Furthermore, the report provides profiles for the leading pharmaceutical companies, Contract Research Organizations (CROs) and distributors; analyzes the macroeconomic environment; describes the healthcare regulations of Argentina and analyzes the strategic consolidations that shape the Argentine pharmaceutical market. This report is built using data and information sourced from proprietary databases, as well as primary and secondary research and in-house analysis by GBI Researchs team of industry experts.

Argentina is the third largest market for pharmaceuticals in Latin America. There are 230 registered laboratories and 110 manufacturing plants in Argentina and most of these are domestic. Over 80% of the laboratories and manufacturing plants are located in urban areas, especially in the province of Buenos Aires. The market has shown significant growth ever since the economic crisis during 2001-2002, due to the ageing population and high proportion of elderly people in the countrys population; growth in government healthcare expenditure; increased internal consumption of medicines and increasing prevalence of diseases which come under major therapy areas such as cardiovascular, Central Nervous System (CNS), gastrointestinal and metabolism, among others. A similarly positive trend is expected in the future due to a number of facts such as increasing internal consumption, a rise in the elderly population favorable strategic consolidations and increasing government healthcare expenditure. GBI Research expects the market to exhibit double-digit growth during the period 20102015.

GBI Research has analyzed the pharmaceutical market in Argentina and found that it is dominated by domestic pharmaceutical companies. Most of the domestic laboratories in Argentina are private and they explored the domestic market. The prescription drugs market accounted for about 90% of the market. Despite issues relating to Intellectual Property (IP) laws, multinational pharmaceutical companies are expanding their market presence by acquiring small domestic laboratories and through licensing agreements. The Argentine pharmaceutical market is one of the top emerging markets which have shown an annual growth rate of up to 22% in recent years. The economic growth of the country has been above the global average and the healthcare sectors expenditure accounted for approximately 10% of the countrys GDP, of which the governments healthcare spending accounted for over 60%.

According to GBI Researchs analysis, Argentina is an attractive market for pharmaceuticals and clinical trials due to a number of factors, such as the aligned legal provisions by Administracin Nacional de Medicamentos, Alimentos y Tecnologa Mdica (ANMAT) (the principal regulatory body in Argentina) and Ministry of Health (MOH); increasing government healthcare spending; favorable healthcare infrastructure; public healthcare programs and a considerable number of licensing, M&As and co-development deals.

Scope

- The overall pharmaceuticals and clinical trials markets in Argentina.
- A pharmaceutical market characterization of the Argentine pharmaceutical market, including market size data and forecast clinical trials, healthcare regulations, pricing, and major marketing and distribution channels.
- The historic and forecast growth of the clinical trials market in Argentina.
- Analysis of the leading segments within the Argentinean pharmaceutical industry.
- Key Argentine ma